CA2652416A1 - Treatment for depressive disorders - Google Patents
Treatment for depressive disorders Download PDFInfo
- Publication number
- CA2652416A1 CA2652416A1 CA002652416A CA2652416A CA2652416A1 CA 2652416 A1 CA2652416 A1 CA 2652416A1 CA 002652416 A CA002652416 A CA 002652416A CA 2652416 A CA2652416 A CA 2652416A CA 2652416 A1 CA2652416 A1 CA 2652416A1
- Authority
- CA
- Canada
- Prior art keywords
- antagonists
- disorder
- antidepressant
- way
- iloperidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000020401 Depressive disease Diseases 0.000 title claims 3
- 238000000034 method Methods 0.000 claims abstract 9
- 239000000556 agonist Substances 0.000 claims abstract 7
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract 5
- 229960003987 melatonin Drugs 0.000 claims abstract 5
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract 5
- 239000005557 antagonist Substances 0.000 claims 24
- -1 2-lodomelatonin Chemical compound 0.000 claims 19
- 239000000935 antidepressant agent Substances 0.000 claims 15
- 229940005513 antidepressants Drugs 0.000 claims 15
- 230000001430 anti-depressive effect Effects 0.000 claims 11
- 206010041250 Social phobia Diseases 0.000 claims 10
- 229960003162 iloperidone Drugs 0.000 claims 7
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims 7
- 208000024714 major depressive disease Diseases 0.000 claims 6
- 239000002207 metabolite Substances 0.000 claims 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 6
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 5
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 5
- 230000000561 anti-psychotic effect Effects 0.000 claims 5
- 208000019906 panic disease Diseases 0.000 claims 5
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 5
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 4
- SBBYBXSFWOLDDG-JLTOFOAXSA-N (2s)-n-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-n-methylpiperazine-1-carboxamide Chemical compound C1([C@H]2CNCCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=CC=C(F)C=C1C SBBYBXSFWOLDDG-JLTOFOAXSA-N 0.000 claims 4
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims 4
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims 4
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 4
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims 4
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 4
- 239000000674 adrenergic antagonist Substances 0.000 claims 4
- 229960002629 agomelatine Drugs 0.000 claims 4
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 claims 4
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 4
- 229950006137 dexfosfoserine Drugs 0.000 claims 4
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims 4
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 4
- NRBNGHCYDWUVLC-UHFFFAOYSA-N mtep Chemical compound S1C(C)=NC(C#CC=2C=NC=CC=2)=C1 NRBNGHCYDWUVLC-UHFFFAOYSA-N 0.000 claims 4
- 229960002296 paroxetine Drugs 0.000 claims 4
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims 4
- 229960003770 reboxetine Drugs 0.000 claims 4
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims 4
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 4
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 4
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 4
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 4
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 4
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims 3
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims 3
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 3
- 201000009916 Postpartum depression Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000029364 generalized anxiety disease Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- VLZBRVJVCCNPRJ-KPHUOKFYSA-N (1S,2S)-2-[(1S)-1-amino-1-carboxy-2-(9H-xanthen-9-yl)ethyl]-1-cyclopropanecarboxylic acid Chemical compound C([C@@H]1[C@](CC2C3=CC=CC=C3OC3=CC=CC=C32)(N)C(O)=O)[C@@H]1C(O)=O VLZBRVJVCCNPRJ-KPHUOKFYSA-N 0.000 claims 2
- FERIKTBTNCSGJS-OBLUMXEWSA-N (1r,2s)-4-aminocyclopentane-1,2,4-tricarboxylic acid Chemical compound OC(=O)C1(N)C[C@H](C(O)=O)[C@H](C(O)=O)C1 FERIKTBTNCSGJS-OBLUMXEWSA-N 0.000 claims 2
- KAGBHVBIOJBGBD-NINOIYOQSA-N (1r,5s)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane;hydrochloride Chemical compound Cl.C1=C(Cl)C(Cl)=CC=C1[C@]1(CNC2)[C@@H]2C1 KAGBHVBIOJBGBD-NINOIYOQSA-N 0.000 claims 2
- XJJZQXUGLLXTHO-ZETCQYMHSA-N (2S)-1-(6-chloro-5-fluoroindol-1-yl)-propan-2-amine Chemical compound FC1=C(Cl)C=C2N(C[C@@H](N)C)C=CC2=C1 XJJZQXUGLLXTHO-ZETCQYMHSA-N 0.000 claims 2
- QLOOWOVVZLBYHU-VIFPVBQESA-N (2s)-1-(7-ethylfuro[2,3-g]indazol-1-yl)propan-2-amine Chemical compound O1C(CC)=CC2=C1C=CC1=C2N(C[C@H](C)N)N=C1 QLOOWOVVZLBYHU-VIFPVBQESA-N 0.000 claims 2
- NJXZWIIMWNEOGJ-WEWKHQNJSA-N (2s,4r)-1-[(3r)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxoindol-3-yl]-4-hydroxy-n,n-dimethylpyrrolidine-2-carboxamide Chemical compound COC1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2[C@@](N2[C@@H](C[C@@H](O)C2)C(=O)N(C)C)(C=2C(=CC=CC=2)OC)C1=O NJXZWIIMWNEOGJ-WEWKHQNJSA-N 0.000 claims 2
- KJEAKWPQCIAVGR-MERQFXBCSA-N (3s)-3-[(5-methoxy-2,3-dihydro-1h-inden-4-yl)oxy]pyrrolidine;hydrochloride Chemical compound Cl.COC1=CC=C2CCCC2=C1O[C@H]1CCNC1 KJEAKWPQCIAVGR-MERQFXBCSA-N 0.000 claims 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 2
- XIGAHNVCEFUYOV-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-n-pyridin-2-ylcyclohexanecarboxamide Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC=CC=C1N1CCN(CCN(C(=O)C2CCCCC2)C=2N=CC=CC=2)CC1 XIGAHNVCEFUYOV-BTJKTKAUSA-N 0.000 claims 2
- HMXQIFUGFZEJEO-UHFFFAOYSA-N 1,2-dihydropyrrol-3-one Chemical class O=C1CNC=C1 HMXQIFUGFZEJEO-UHFFFAOYSA-N 0.000 claims 2
- DXNOFPQQCQAJFH-MRXNPFEDSA-N 1-(2-iodophenyl)-n-[3-[[(2r)-pyrrolidin-2-yl]methyl]-1h-indol-5-yl]methanesulfonamide Chemical compound IC1=CC=CC=C1CS(=O)(=O)NC1=CC=C(NC=C2C[C@@H]3NCCC3)C2=C1 DXNOFPQQCQAJFH-MRXNPFEDSA-N 0.000 claims 2
- GHAMYXPEZSUOCU-XZOQPEGZSA-N 1-[2-[4-[(1r,3s)-3-(4-fluorophenyl)-2,3-dihydro-1h-inden-1-yl]piperazin-1-yl]ethyl]imidazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@H]1C2=CC=CC=C2[C@H](N2CCN(CCN3C(NCC3)=O)CC2)C1 GHAMYXPEZSUOCU-XZOQPEGZSA-N 0.000 claims 2
- JSXDLWRIIOHHIC-UHFFFAOYSA-N 1H-cyclopropa[b]chromene-1a-carboxamide Chemical compound C1=CC=C2OC(C3)(C(=O)N)C3=CC2=C1 JSXDLWRIIOHHIC-UHFFFAOYSA-N 0.000 claims 2
- LJUNPHMOGNFFOS-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-6-yl(piperidin-1-yl)methanone Chemical compound C=1C=C2OCCOC2=CC=1C(=O)N1CCCCC1 LJUNPHMOGNFFOS-UHFFFAOYSA-N 0.000 claims 2
- NZDIZJGEDFARSV-UHFFFAOYSA-N 2-amino-4-(5-methyl-3-oxo-1,2-oxazol-4-yl)butanoic acid Chemical compound CC=1ONC(=O)C=1CCC(N)C(O)=O NZDIZJGEDFARSV-UHFFFAOYSA-N 0.000 claims 2
- QOTAQTRFJWLFCR-UHFFFAOYSA-N 3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl-(4-methoxycyclohexyl)methanone Chemical compound C1CC(OC)CCC1C(=O)C1=CC=C(N=C2C(CCCO2)=C2)C2=C1 QOTAQTRFJWLFCR-UHFFFAOYSA-N 0.000 claims 2
- QBBJSFUFEUXTNU-UHFFFAOYSA-N 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-n-pentan-3-ylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CC1=NN2C(NC(CC)CC)=CC(C)=NC2=C1C1=CC=C(OC)C=C1C QBBJSFUFEUXTNU-UHFFFAOYSA-N 0.000 claims 2
- JCFULPDIJOVUHP-KSSFIOAISA-N 3-[(1s)-1-[[(2s)-3-[cyclohexylmethyl(hydroxy)phosphoryl]-2-hydroxypropyl]amino]ethyl]benzoic acid Chemical compound C([C@@H](O)CN[C@@H](C)C=1C=C(C=CC=1)C(O)=O)P(O)(=O)CC1CCCCC1 JCFULPDIJOVUHP-KSSFIOAISA-N 0.000 claims 2
- ONNMDRQRSGKZCN-UHFFFAOYSA-N 3-aminopropyl(butyl)phosphinic acid Chemical compound CCCCP(O)(=O)CCCN ONNMDRQRSGKZCN-UHFFFAOYSA-N 0.000 claims 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 claims 2
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 claims 2
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 claims 2
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 claims 2
- GIUZEIJUFOPTMR-UHFFFAOYSA-N 6-chloro-5-methyl-n-[6-(2-methylpyridin-3-yl)oxypyridin-3-yl]-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(Cl)C(C)=CC=2CCN1C(=O)NC(C=N1)=CC=C1OC1=CC=CN=C1C GIUZEIJUFOPTMR-UHFFFAOYSA-N 0.000 claims 2
- PHGWDAICBXUJDU-UHFFFAOYSA-N 8,9-dichloro-1,2,3,4,4a,6-hexahydropyrazino[1,2-a]quinoxalin-5-one Chemical compound N1C(=O)C2CNCCN2C2=C1C=C(Cl)C(Cl)=C2 PHGWDAICBXUJDU-UHFFFAOYSA-N 0.000 claims 2
- MDWRPTOUDPFXKK-UHFFFAOYSA-N 8-(2,4-dichlorophenyl)-n-(1,3-dimethoxypropan-2-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound CC1=NN2C(NC(COC)COC)=NC(C)=NC2=C1C1=CC=C(Cl)C=C1Cl MDWRPTOUDPFXKK-UHFFFAOYSA-N 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 101800001144 Arg-vasopressin Proteins 0.000 claims 2
- 102400000059 Arg-vasopressin Human genes 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 2
- ANDGGVOPIJEHOF-UHFFFAOYSA-N CX-516 Chemical compound C=1C=C2N=CC=NC2=CC=1C(=O)N1CCCCC1 ANDGGVOPIJEHOF-UHFFFAOYSA-N 0.000 claims 2
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 claims 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 claims 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 claims 2
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims 2
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 2
- 229930195711 D-Serine Natural products 0.000 claims 2
- JFHJGXQFESYQGY-UHFFFAOYSA-N Emicerfont Chemical compound CC1=CC(OC)=CC=C1N1C(N=C(C)C=C2N3N=C(C=C3)N3C(NCC3)=O)=C2CC1 JFHJGXQFESYQGY-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 101000878678 Homo sapiens Corticotropin-releasing factor receptor 1 Proteins 0.000 claims 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 2
- 229930195714 L-glutamate Natural products 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- OIGHTPDWPMLMGT-UHFFFAOYSA-N LSM-3233 Chemical compound C1CNCC2=CC=CC3=C2N1C1=C3CCCC1 OIGHTPDWPMLMGT-UHFFFAOYSA-N 0.000 claims 2
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 claims 2
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 claims 2
- OFCLARYYBGKCHN-UHFFFAOYSA-N N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide Chemical compound CC(=O)NCCC=1C2=CC(OC)=CC=C2NC=1C1=CC=CC=C1 OFCLARYYBGKCHN-UHFFFAOYSA-N 0.000 claims 2
- LUINDDOUWHRIPW-UHFFFAOYSA-N N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)ethyl]acetamide Chemical compound C1=C(Cl)C(OC)=CC2=C1NC=C2CCNC(C)=O LUINDDOUWHRIPW-UHFFFAOYSA-N 0.000 claims 2
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 claims 2
- HZZZZODVDSHQRG-UHFFFAOYSA-N N-[5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxopentyl]-2,4-dimethoxyphenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound COC1=CC(OC)=C(C(=O)CCCCN2CCC3(CC2)C(NC(=O)N3)=O)C=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 HZZZZODVDSHQRG-UHFFFAOYSA-N 0.000 claims 2
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 claims 2
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 claims 2
- ATQMRMGXINTJHV-UHFFFAOYSA-N SB 224289 Chemical compound C1CN(C)CCC11C2=CC(N(C(=O)C=3C=CC(=CC=3)C=3C(=CC(=CC=3)C=3N=C(C)ON=3)C)CC3)=C3C=C2OC1 ATQMRMGXINTJHV-UHFFFAOYSA-N 0.000 claims 2
- IEAKXXNRGSLYTQ-DEOSSOPVSA-N SSR 125543 Chemical compound C1=C(C)C(OC)=CC(Cl)=C1C1=C(C)SC(N(CC#C)[C@@H](CC2CC2)C=2C=C(F)C(C)=CC=2)=N1 IEAKXXNRGSLYTQ-DEOSSOPVSA-N 0.000 claims 2
- 101000948733 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Probable phospholipid translocase non-catalytic subunit CRF1 Proteins 0.000 claims 2
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 claims 2
- 229960000793 aniracetam Drugs 0.000 claims 2
- IXPROWGEHNVJOY-UHFFFAOYSA-N antalarmin Chemical compound CC1=C(C)C=2C(N(CC)CCCC)=NC(C)=NC=2N1C1=C(C)C=C(C)C=C1C IXPROWGEHNVJOY-UHFFFAOYSA-N 0.000 claims 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 2
- 229940049706 benzodiazepine Drugs 0.000 claims 2
- 150000001557 benzodiazepines Chemical class 0.000 claims 2
- 229960001058 bupropion Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 claims 2
- 229960003176 cyclothiazide Drugs 0.000 claims 2
- QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000024732 dysthymic disease Diseases 0.000 claims 2
- 229940098766 effexor Drugs 0.000 claims 2
- VTAARTQTOOYTES-RGDLXGNYSA-N eglumegad Chemical compound OC(=O)[C@]1(N)CC[C@H]2[C@H](C(O)=O)[C@@H]12 VTAARTQTOOYTES-RGDLXGNYSA-N 0.000 claims 2
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 claims 2
- 229960003472 felbamate Drugs 0.000 claims 2
- 229960002464 fluoxetine Drugs 0.000 claims 2
- 229960002449 glycine Drugs 0.000 claims 2
- 229960003998 ifenprodil Drugs 0.000 claims 2
- 229950008734 irindalone Drugs 0.000 claims 2
- 229960003299 ketamine Drugs 0.000 claims 2
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 claims 2
- 229960005417 ketanserin Drugs 0.000 claims 2
- HOQAVGZLYRYHSO-UHFFFAOYSA-N ly-404,187 Chemical compound C1=CC(C(C)CNS(=O)(=O)C(C)C)=CC=C1C1=CC=C(C#N)C=C1 HOQAVGZLYRYHSO-UHFFFAOYSA-N 0.000 claims 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 2
- 229960004640 memantine Drugs 0.000 claims 2
- LFAGGDAZZKUVKO-JAGWWQSPSA-N mgs-0039 Chemical compound O([C@@H]1C[C@@H]2[C@@H]([C@@]2(F)C(O)=O)[C@]1(N)C(O)=O)CC1=CC=C(Cl)C(Cl)=C1 LFAGGDAZZKUVKO-JAGWWQSPSA-N 0.000 claims 2
- 229960001785 mirtazapine Drugs 0.000 claims 2
- RVIGBTUDFAGRTQ-LLVKDONJSA-N n-[(2r)-8-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl]propanamide Chemical compound C1=CC(OC)=C2C[C@H](NC(=O)CC)CCC2=C1 RVIGBTUDFAGRTQ-LLVKDONJSA-N 0.000 claims 2
- QFAUPDBCVKBKSH-UHFFFAOYSA-N n-[2-(4-thiophen-3-ylphenyl)propyl]propane-2-sulfonamide Chemical compound C1=CC(C(C)CNS(=O)(=O)C(C)C)=CC=C1C1=CSC=C1 QFAUPDBCVKBKSH-UHFFFAOYSA-N 0.000 claims 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 2
- 229960002508 pindolol Drugs 0.000 claims 2
- 229960004526 piracetam Drugs 0.000 claims 2
- 229940035613 prozac Drugs 0.000 claims 2
- 229960001150 ramelteon Drugs 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 229940023942 remeron Drugs 0.000 claims 2
- PGKXDIMONUAMFR-AREMUKBSSA-N saredutant Chemical compound C([C@H](CN(C)C(=O)C=1C=CC=CC=1)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1(NC(C)=O)C1=CC=CC=C1 PGKXDIMONUAMFR-AREMUKBSSA-N 0.000 claims 2
- 229940076279 serotonin Drugs 0.000 claims 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 2
- 229960002073 sertraline Drugs 0.000 claims 2
- 229960004688 venlafaxine Drugs 0.000 claims 2
- 229950007305 vestipitant Drugs 0.000 claims 2
- XOSKJKGKWRIMGV-DGCLKSJQSA-N way-163909 Chemical compound C1NCCN2[C@@H]3CCC[C@@H]3C3=CC=CC1=C32 XOSKJKGKWRIMGV-DGCLKSJQSA-N 0.000 claims 2
- 229940009065 wellbutrin Drugs 0.000 claims 2
- 229940020965 zoloft Drugs 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010010144 Completed suicide Diseases 0.000 claims 1
- 206010011971 Decreased interest Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- FJDDSMSDZHURBJ-UHFFFAOYSA-N N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide Chemical compound COC1=CC=C2NC(I)=C(CCNC(C)=O)C2=C1 FJDDSMSDZHURBJ-UHFFFAOYSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000001431 Psychomotor Agitation Diseases 0.000 claims 1
- 206010038743 Restlessness Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010042464 Suicide attempt Diseases 0.000 claims 1
- 206010068932 Terminal insomnia Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940124604 anti-psychotic medication Drugs 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74786106P | 2006-05-22 | 2006-05-22 | |
| US60/747,861 | 2006-05-22 | ||
| PCT/US2007/069373 WO2007137227A1 (en) | 2006-05-22 | 2007-05-21 | Treatment for depressive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2652416A1 true CA2652416A1 (en) | 2007-11-29 |
Family
ID=38723631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002652416A Abandoned CA2652416A1 (en) | 2006-05-22 | 2007-05-21 | Treatment for depressive disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090306137A1 (enExample) |
| EP (1) | EP2029136A4 (enExample) |
| JP (1) | JP2009538331A (enExample) |
| KR (1) | KR20090029200A (enExample) |
| AU (1) | AU2007253684A1 (enExample) |
| BR (1) | BRPI0711872A2 (enExample) |
| CA (1) | CA2652416A1 (enExample) |
| MX (1) | MX2008014843A (enExample) |
| RU (1) | RU2008150624A (enExample) |
| WO (1) | WO2007137227A1 (enExample) |
| ZA (1) | ZA200809528B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8362277B2 (en) * | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| WO2010081115A1 (en) | 2009-01-09 | 2010-07-15 | University Of Texas Southwestern Medical Center | Pro-neurogenic compounds |
| US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
| MX2012007365A (es) | 2009-12-23 | 2012-08-15 | Lupin Ltd | Composiciones farmaceuticas de liberacion lenta de iloperidona. |
| FR2956031B1 (fr) * | 2010-02-11 | 2012-03-02 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc) |
| CN103415289B (zh) | 2010-07-07 | 2017-04-12 | 得克萨斯州大学系统董事会 | 前神经原性化合物 |
| CN103429223A (zh) * | 2011-01-17 | 2013-12-04 | 武田药品工业株式会社 | 口腔分散片 |
| US8426461B2 (en) | 2011-01-17 | 2013-04-23 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
| FR2978916B1 (fr) * | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| RU2465895C1 (ru) * | 2011-09-08 | 2012-11-10 | Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" | Способ лечения депрессивного невроза |
| WO2013054582A1 (en) * | 2011-10-14 | 2013-04-18 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
| US20130236573A1 (en) * | 2012-03-12 | 2013-09-12 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| EP2825167B1 (en) | 2012-03-14 | 2018-05-09 | Vanda Pharmaceuticals Inc. | An iloperidone metabolite for use in the treatment of psychiatric disorders |
| EP2841068B8 (en) * | 2012-04-23 | 2019-03-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
| MX2014014010A (es) | 2012-05-18 | 2015-02-12 | Vanda Pharmaceuticals Inc | Metabolitos de (1r-trans) -n - [[2- (2,3-dihidro-4-benzofuranilo) ciclopropilo] metilo] propanamida. |
| RU2488388C1 (ru) * | 2012-05-24 | 2013-07-27 | Ооо "Валента Интеллект" | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
| GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| CA2882826A1 (en) | 2012-08-24 | 2014-02-27 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
| WO2014120936A2 (en) | 2013-01-30 | 2014-08-07 | Pharmorx Therapeutics, Inc. | Treatments for depression and other diseases with a low dose agent |
| PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
| KR101484405B1 (ko) * | 2013-08-14 | 2015-01-19 | 서울대학교산학협력단 | Ｎｉｎｊｕｒｉｎ１ 결핍 유래의 강박증 예방 또는 치료용 약학적 조성물 |
| EP3068388A4 (en) | 2013-11-11 | 2017-04-12 | Board of Regents of the University of Texas System | Neuroprotective compounds and use thereof |
| WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
| CA3155599A1 (en) | 2014-01-21 | 2015-07-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
| RU2571546C1 (ru) * | 2014-07-14 | 2015-12-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ дифференцированной диагностики и терапии синдрома ночной еды |
| CA2957926A1 (en) | 2014-08-13 | 2016-02-18 | Janssen Pharmaceutica Nv | Method for the treatment of depression |
| KR20170054470A (ko) | 2014-09-15 | 2017-05-17 | 얀센 파마슈티카 엔.브이. | VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법 |
| US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9744239B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| IL275482B1 (en) | 2017-12-22 | 2025-03-01 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| EP3505157B1 (en) | 2017-12-29 | 2021-12-08 | Celon Pharma S.A. | Dry powder ketamine composition for pulmonary administration in treatment-resistant depression |
| MA56226A (fr) | 2018-12-07 | 2022-04-20 | Neurocrine Biosciences Inc | Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale |
| WO2020178653A1 (en) | 2019-03-05 | 2020-09-10 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| CN118252829A (zh) | 2019-09-27 | 2024-06-28 | 纽罗克里生物科学有限公司 | Crf受体拮抗剂及使用方法 |
| EP4065109A4 (en) | 2019-11-27 | 2023-09-13 | Neurorive Inc | CYCLOSERINE AND LITHIUM COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION |
| IL295374A (en) * | 2020-02-04 | 2022-10-01 | Mindset Pharma Inc | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| US5776963A (en) | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| AU2927392A (en) | 1991-11-01 | 1993-06-07 | National-Standard Company | Age resistant solder coatings |
| MXPA03006003A (es) * | 2001-01-02 | 2005-09-08 | Upjohn Co | Nuevas combinaciones de farmacos. |
| GB0102841D0 (en) * | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
| US20020123490A1 (en) * | 2001-03-01 | 2002-09-05 | Pfizer Inc. | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis |
| ATE518845T1 (de) * | 2001-08-31 | 2011-08-15 | Novartis Pharma Gmbh | Optische isomere eines iloperidon-metaboliten |
| CA2463158C (en) | 2001-10-30 | 2013-07-30 | Novartis Ag | Depot formulations of iloperidone and a star polymer |
| SI1458888T1 (sl) | 2001-12-10 | 2011-07-29 | Novartis Ag | Metode zdravljenja psihoze in shizofrenije na osnovi polimorfizmov gena cntf |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| US6831077B2 (en) * | 2002-07-25 | 2004-12-14 | Comprehensive Neuroscience, Inc. | Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation |
| MXPA05000294A (es) * | 2002-07-30 | 2005-08-19 | Peter Migaly | Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas. |
| US20050203130A1 (en) * | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| EP1799865B1 (en) * | 2004-09-30 | 2012-06-06 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
-
2007
- 2007-05-21 BR BRPI0711872-4A patent/BRPI0711872A2/pt not_active IP Right Cessation
- 2007-05-21 US US12/301,675 patent/US20090306137A1/en not_active Abandoned
- 2007-05-21 EP EP07783990A patent/EP2029136A4/en not_active Ceased
- 2007-05-21 CA CA002652416A patent/CA2652416A1/en not_active Abandoned
- 2007-05-21 MX MX2008014843A patent/MX2008014843A/es unknown
- 2007-05-21 RU RU2008150624/14A patent/RU2008150624A/ru not_active Application Discontinuation
- 2007-05-21 WO PCT/US2007/069373 patent/WO2007137227A1/en not_active Ceased
- 2007-05-21 AU AU2007253684A patent/AU2007253684A1/en not_active Abandoned
- 2007-05-21 KR KR1020087029908A patent/KR20090029200A/ko not_active Ceased
- 2007-05-21 JP JP2009512244A patent/JP2009538331A/ja active Pending
-
2008
- 2008-11-07 ZA ZA200809528A patent/ZA200809528B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0711872A2 (pt) | 2011-12-06 |
| MX2008014843A (es) | 2008-12-05 |
| WO2007137227A1 (en) | 2007-11-29 |
| KR20090029200A (ko) | 2009-03-20 |
| US20090306137A1 (en) | 2009-12-10 |
| EP2029136A4 (en) | 2010-01-06 |
| AU2007253684A1 (en) | 2007-11-29 |
| ZA200809528B (en) | 2009-11-25 |
| RU2008150624A (ru) | 2010-06-27 |
| EP2029136A1 (en) | 2009-03-04 |
| JP2009538331A (ja) | 2009-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090306137A1 (en) | Treatment for depressive disorders | |
| RU2445973C2 (ru) | Способ лечения глубокой депрессии у человека | |
| US20200197388A1 (en) | Treatments for depression and other diseases with a low dose agent | |
| JP2009511618A (ja) | 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用 | |
| JP2008536946A (ja) | うつ病の処置または予防のための新規の治療的組み合わせ | |
| ES2625142T3 (es) | Usos terapéuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]-piperacina | |
| PROFILE | Pharmacology of antidepressants: focus on nefazodone | |
| PT1628652E (pt) | Combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão | |
| JP2007523052A (ja) | 鬱病の処置のための蘇生薬モダフィニルおよび抗鬱薬の組み合わせ | |
| AU6378199A (en) | A new composition | |
| US20060217394A1 (en) | Treatment of anhedonia | |
| AU6377999A (en) | A new composition | |
| HK1119077A (en) | Combinations of eszopiclone and an antidepressant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20141113 |